S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PLRX · Pliant Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Pliant Therapeutics Inc (PLRX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.89
-0.02
(-2.40%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.89
$0.89
$0.92
52-WEEK RANGE
$0.89
$0.88
$1.95
What's happening
- PLRX is down 2.40% today, trading at $0.89. — Live quote
- It's trading within 3% of its 52-week low ($0.88). (Finnhub fundamentals)
- Volume today (4,852) is well below its 3-month average of 467,860. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.36 actual vs. $-0.35 estimated (-3.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 5
Sell 2
Strong sell 2
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PLRX
-25.21%
vs S&P 500
-37.99%
1-YEAR RETURN
PLRX
-44.37%
vs S&P 500
-58.93%
6-MONTH RETURN
PLRX
-29.82%
3-MONTH RETURN
PLRX
-16.29%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.36
Est. $-0.35
MISS -3.2%
2026-04-26 (Q1 2026)
$-0.32
Est. $-0.36
BEAT +12.0%
2026-01-26 (Q4 2025)
$-0.38
Est. $-0.39
BEAT +1.5%
2025-10-26 (Q3 2025)
$-0.43
Est. $-0.53
BEAT +19.5%
Valuation Measures & Ratios
Enterprise Value4$30.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)10.90
Price / Book70.48
EV4 / Revenue5.96
EV4 / EBITDA—
Profit Margin-2871.17%
Operating Margin-3156.66%
Return on Equity (ROE8)-69.56%
Return on Assets (ROA9)-52.11%
Avg Volume (3M)467,860
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $70.8M | $79.8M | $90.2M | $71.0M | $82.4M |
| P/E | -0.63 | -0.55 | -0.49 | -0.33 | -0.38 |
| Price/Book | 0.48 | 0.48 | 0.45 | 0.32 | 0.32 |
| ROE | -76.24% | -88.28% | -91.62% | -96.82% | -84.28% |
| ROA | -58.99% | -71.97% | -66.35% | -71.07% | -62.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,246,484
Change from Prior Settlement+15.01%
% of Float—
Days to Cover (Short Ratio)11.40
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -2871.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -44.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PLRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| Operating income | -$23.9M | -$21.8M | -$28.3M | -$45.6M | -$58.9M | -$62.0M | -$60.6M | -$52.4M |
| Net income | -$22.4M | -$20.0M | -$26.3M | -$43.3M | -$56.2M | -$57.8M | -$55.9M | -$47.0M |
| EPS (diluted) | $-0.36 | $-0.32 | $-0.43 | $-0.71 | $-0.92 | $-0.95 | $-0.92 | $-0.78 |
| EPS (basic) | $-0.36 | $-0.32 | $-0.43 | $-0.71 | $-0.92 | $-0.95 | $-0.92 | $-0.78 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $189.9M | $202.6M | $225.2M | $276.6M | $299.8M | $344.8M | $396.9M | $445.7M |
| Total liabilities | $43.0M | $37.4M | $44.0M | $76.3M | $79.7M | $87.6M | $92.9M | $99.8M |
| Stockholders' equity | $146.9M | $165.2M | $181.2M | $200.3M | $220.1M | $257.2M | $304.1M | $345.8M |
| Total current assets | $163.1M | $174.9M | $196.4M | $245.6M | $267.4M | $311.2M | $362.3M | $410.0M |
| Total current liabilities | $16.5M | $10.4M | $16.4M | $17.6M | $20.6M | $28.2M | $33.2M | $40.0M |
| Cash & equivalents | $24.9M | $22.2M | $45.4M | $93.7M | $86.8M | $91.9M | $71.2M | $79.6M |
| Marketable securities (current) | $133.2M | $148.7M | $145.5M | $148.1M | $176.1M | $213.7M | $284.5M | $324.9M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $2.4M | $2.7M | $2.9M | $4.3M | $4.9M | $5.2M | $5.5M | $5.7M |
| Other non-current assets | $554.0K | $389.0K | $392.0K | $392.0K | $391.0K | $427.0K | $435.0K | $427.0K |
| Accounts payable | $1.5M | $362.0K | $480.0K | $485.0K | $1.4M | $5.6M | $6.0M | $6.9M |
| Accrued liabilities | $3.7M | $4.1M | $9.6M | $8.2M | $7.2M | $7.4M | $12.4M | $9.7M |
| Long-term debt | $0 | $0 | $0 | $30.4M | $30.4M | $30.3M | $30.2M | $30.1M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$901.8M | -$879.4M | -$859.4M | -$835.8M | -$809.5M | -$766.2M | -$710.1M | -$660.3M |
| Accumulated other comprehensive income (loss) | -$397.0K | -$341.0K | -$15.0K | $34.0K | -$1.0K | $159.0K | $321.0K | $848.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.8M | -$19.2M | -$17.8M | -$21.1M | -$40.6M | -$48.9M | -$47.7M | -$32.3M |
| Investing cash flow | $15.5M | -$4.1M | $1.8M | $27.9M | $35.5M | $69.1M | $39.1M | $31.0M |
| Financing cash flow | $0 | $74.0K | -$32.3M | $72.0K | $0 | $498.0K | $102.0K | $543.0K |
| Free cash flow | -$12.8M | -$19.2M | -$17.8M | -$21.1M | -$40.7M | -$49.1M | -$47.9M | -$33.2M |
| Capital expenditures | $0 | $0 | $0 | $0 | $112.0K | $262.0K | $209.0K | $896.0K |
| Share-based compensation | $4.2M | $4.3M | $4.5M | $6.4M | $6.4M | $8.9M | $8.4M | $8.9M |
| Change in accounts receivable | — | — | — | — | — | — | $0 | $0 |
| Change in accounts payable | $1.2M | -$118.0K | -$3.0K | -$897.0K | -$4.2M | -$338.0K | -$930.0K | $3.7M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| EPS (basic) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| Operating margin | — | — | -$11.7K | -$1.3K | -$1.3K |
| Net margin | — | — | -$10.2K | -$1.3K | -$1.3K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Stockholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
| Total current assets | $196.4M | $362.3M | $505.5M | $340.3M | $209.4M |
| Total current liabilities | $16.4M | $33.2M | $28.5M | $23.9M | $16.8M |
| Cash & equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M |
| Marketable securities (current) | $145.5M | $284.5M | $431.0M | $297.5M | $148.9M |
| Accounts receivable | — | — | $0 | $2.0M | $2.0M |
| Property, plant & equipment | $2.9M | $5.5M | $3.6M | $4.5M | $4.6M |
| Other non-current assets | $392.0K | $435.0K | $392.0K | $394.0K | $838.0K |
| Accounts payable | $480.0K | $6.0M | $4.5M | $1.6M | $3.0M |
| Accrued liabilities | $9.6M | $12.4M | $10.2M | $8.7M | $12.0M |
| Long-term debt | $0 | $30.2M | $10.1M | $9.9M | $0 |
| Other non-current liabilities | — | — | — | — | $0 |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $5.0K | $3.0K |
| Retained earnings | -$859.4M | -$710.1M | -$499.7M | -$338.4M | -$215.1M |
| Accumulated other comprehensive income (loss) | -$15.0K | $321.0K | $345.0K | -$2.0M | -$201.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Investing cash flow | $134.3M | $140.3M | -$127.0M | -$150.2M | $73.7M |
| Financing cash flow | -$31.7M | $23.1M | $274.4M | $226.9M | $2.5M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
| Capital expenditures | $374.0K | $3.8M | $921.0K | $1.8M | $2.0M |
| Share-based compensation | $26.2M | $37.6M | $44.5M | $22.6M | $10.4M |
| Change in accounts receivable | — | $0 | -$2.0M | -$15.0K | -$7.3M |
| Change in accounts payable | -$5.5M | $1.4M | $3.0M | -$1.4M | $891.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PLRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-09 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about PLRX (Pliant Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research
Investing News Network · 2026-10-21 -
Pliant Therapeutics appoints Craig Blanchette as SVP, Research By Investing.com
Investing.com Nigeria · 2026-10-20 -
Pliant Therapeutics names Craig Blanchette SVP of Research to boost RNAi drug delivery platform.
Pluang · 2026-10-20 -
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Yahoo Finance · 2026-10-20 -
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Yahoo Finance · 2026-10-19 -
PLRX Oct 2026 2.000 call (PLRX261016C00002000) Stock Historical Prices & Data
Yahoo! Finance Canada · 2026-10-15 -
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Yahoo Finance · 2026-09-30 -
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Yahoo Finance · 2026-08-18
No headlines in this category right now — try “All”.